Plain-English translation of NCT03673748 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Lupus Nephritis research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a treatment called MSV-allo, which uses mesenchymal stem cells—special cells that may help reduce inflammation and repair kidney damage caused by lupus. You would receive a single intravenous infusion of these cells (or a placebo) and continue taking your regular lupus medications. Researchers want to see if this treatment can improve kidney function and lupus symptoms in people whose disease hasn't responded well to standard therapy.
Many people with lupus-related kidney disease don't get better with conventional treatments alone, and their kidneys continue to deteriorate. This medication is being tested because stem cells may have unique ability to calm the immune system and help repair kidney tissue in ways that current drugs cannot.
You likely qualify if…
You likely don't qualify if…
If you qualify and are randomly assigned to receive the treatment, you would come in for a single visit where you receive an intravenous infusion of stem cells (or placebo saline solution if you are in the placebo group). The infusion takes place over about 100 milliliters of fluid. You would continue taking all of your regular lupus medications throughout the trial, and the research team would monitor you over time to see how your kidneys respond and whether your lupus symptoms improve. The trial involves 20 participants total.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
Spain